BACKGROUND: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. OBJECTIVE: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). METHOD: The authors performed a chart review of HCV patients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. RESULTS: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. CONCLUSION: Patients with MDD can be safely and effectively treated with antiviral therapy.
BACKGROUND: Despite evidence suggesting that the majority of patients with hepatitis C virus (HCV) have psychiatric and substance use disorders, patients with these comorbidities have historically been excluded from antiviral therapy for HCV. OBJECTIVE: The authors compared antiviral completion and sustained virologic response (SVR) rates between hepatitis C (HCV) patients with versus those without preexisting major depressive disorder (MDD). METHOD: The authors performed a chart review of HCVpatients (30 with MDD and 25 control subjects) who attended an optional HCV education class and signed informed consent allowing collection of clinical data. RESULTS: The MDD group had completion and SVR rates similar to those of control subjects. Neuropsychiatric side effects and reasons for discontinuation of treatment were not different between groups. CONCLUSION:Patients with MDD can be safely and effectively treated with antiviral therapy.
Authors: S Chainuvati; S K Khalid; S Kancir; M Shea; J Edwards; M Sernyak; S Wongcharatrawee; G Garcia-Tsao Journal: J Viral Hepat Date: 2006-04 Impact factor: 3.728
Authors: D H Van Thiel; L Friedlander; P J Molloy; S Fagiuoli; R J Kania; P Caraceni Journal: Eur J Gastroenterol Hepatol Date: 1995-02 Impact factor: 2.566
Authors: Jeffrey J Weiss; Sarah Prieto; Norbert Bräu; Douglas T Dieterich; Sue M Marcus; Alicia Stivala; Jack M Gorman Journal: Int J Psychiatry Med Date: 2018-01-03 Impact factor: 1.210
Authors: Jennifer M Loftis; Alexander L Patterson; Clare J Wilhelm; Henry McNett; Benjamin J Morasco; Marilyn Huckans; Timothy Morgan; Shira Saperstein; Aliya Asghar; Peter Hauser Journal: J Psychosom Res Date: 2012-11-21 Impact factor: 3.006
Authors: Marilyn Huckans; Bret Fuller; Viva Wheaton; Sarah Jaehnert; Carilyn Ellis; Michael Kolessar; Daniel Kriz; Jeanne Renee Anderson; Kristin Berggren; Hannah Olavarria; Anna W Sasaki; Michael Chang; Kenneth D Flora; Jennifer M Loftis Journal: J Psychosom Res Date: 2014-08-07 Impact factor: 3.006